Diclofenac Prodrugs for Intra-articular Depot Injectables: In Vitro Hydrolysis and Species Variation.

This study examines five different types of diclofenac ester prodrugs for their potential use in depot injections for treating joint pain. The prodrugs break down at different rates in various species and environments, with the fastest half-lives registered in human synovial fluid and plasma.

Research Objectives

• The primary objective of this research was to analyze the synthetic production, physicochemical properties, and in-vitro bioconversion rates of five different prodrugs of diclofenac.
• These prodrugs are intended for use in depot injections for joint pain treatment—specifically, joint inflammation, commonly treated with non-steroidal anti-inflammatory drugs (NSAIDs). Depot injections involve using a suspension of the drug, which is released slowly into the body.
• The prodrugs were designed with varying imidazole promoieties, assistive agents meant to promote or enhance their intended effect.

Methods and Results

• The research team synthesized the five diclofenac prodrugs and characterized their physicochemical properties. They then examined the in-vitro hydrolysis rates of these prodrugs in buffered solutions, and in plasma and synovial fluid (a lubricating liquid found in joints) of humans, horses, dogs, and rats.
• The hydrolysis process, by which these prodrugs break down, is enzyme-mediated and observes pseudo-first-order kinetics, meaning the reaction rate is proportionate to the quantity of one reactant.
• The study observed large variations in the hydrolysis rates between the species and prodrugs tested. The fastest half-lives (time taken for the drug to halve in concentration) were noted in the human and equine synovial fluid, while the slowest were found in rat and dog plasma.

Discussion and Conclusion

• The results emphasise how species differences and tissue types play a significant role in prodrug design, and how these factors should be carefully considered during the creation of new drug formulations.
• The study suggests that the horse may represent a suitable model for testing this intra-articular depot approach, due to the similarities in the bioconversion rates of horses and humans.
• Based on their rapid in-vitro enzyme-mediated bioconversion to diclofenac and their physiochemical characteristics, two of the prodrug candidates were identified as particularly promising for future in vivo investigations.